双鹭药业(002038) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥252,832,785.33, representing a 29.88% increase compared to ¥194,660,284.30 in the same period last year[9]. - Net profit attributable to shareholders was ¥91,830,018.08, up 49.12% from ¥61,582,818.21 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥66,422,502.97, reflecting a 55.11% increase from ¥42,821,601.46 in the previous year[9]. - Basic earnings per share were ¥0.09, a 50.00% increase from ¥0.06 year-on-year[9]. - The company's operating revenue and net profit attributable to shareholders increased by 29.88% and 49.12% year-on-year, respectively, due to increased product sales and overall revenue[24]. - The estimated net profit for the first half of 2021 is projected to be between 27,549.24 million and 31,484.85 million, indicating a growth of 40.00% to 60.00% compared to the previous year[31]. - Basic earnings per share are expected to rise to between 0.2681 and 0.3064, representing a growth of 40.00% to 60.00% year-on-year[31]. - The net profit for the current period was ¥89,530,588.26, compared to ¥60,144,865.93 in the previous period, indicating a year-over-year increase of about 48.8%[65]. - The total profit for the current period was ¥104,730,620.64, compared to ¥66,412,925.50 in the previous period, marking an increase of around 57.6%[65]. - The company's basic earnings per share increased to ¥0.09 from ¥0.06, representing a growth of 50%[69]. - The total comprehensive income for the current period was ¥91,312,574.99, compared to ¥66,763,094.26 in the previous period, showing an increase of approximately 36.7%[69]. - The company reported investment income of ¥24,280,027.99, significantly higher than ¥11,951,821.39 from the previous period, indicating a growth of about 102.8%[65]. Cash Flow and Liquidity - The net cash flow from operating activities reached ¥77,482,058.85, an 88.39% increase compared to ¥41,129,600.32 in the same period last year[9]. - Cash inflow from operating activities totaled ¥302,881,348.85, compared to ¥295,809,369.17 in the prior period, indicating a year-over-year increase[81]. - Investment activities generated a net cash flow of ¥62,385,695.46, a substantial recovery from a negative cash flow of -¥498,296,947.00 in the prior period[81]. - Cash and cash equivalents at the end of the period were ¥812,366,498.58, compared to ¥802,854,208.15 at the end of the previous period, reflecting a slight increase[83]. - The company reported a net increase in cash and cash equivalents of ¥148,886,514.99, contrasting with a decrease of -¥458,009,564.07 in the previous period[83]. - The company received cash from sales of goods and services amounting to ¥298,111,198.74, compared to ¥289,186,967.26 in the previous period[77]. - Cash outflow for purchasing goods and services was ¥83,817,815.78, down from ¥100,857,004.66 in the prior period, indicating cost management efforts[81]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,515,951,287.61, a 2.25% increase from ¥5,394,828,767.77 at the end of the previous year[9]. - The total liabilities amounted to ¥409,787,784.71, slightly down from ¥410,093,857.05 in the previous period[50]. - Total equity attributable to shareholders of the parent company increased to ¥5,088,699,781.62 from ¥4,974,606,534.39, reflecting a growth of about 2.3%[50]. - The total non-current liabilities decreased to ¥90,550,753.33 from ¥95,118,362.98, a reduction of approximately 4.8%[50]. - The company's cash and cash equivalents increased to 812,366,498.58 yuan from 663,479,983.59 yuan[41]. - The total current assets reached 2,262,115,879.97 yuan, compared to 2,207,336,742.86 yuan in the previous period[41]. - The company holds trading financial assets valued at 151,974,753.16 yuan, down from 173,810,699.93 yuan[41]. - The company's inventory decreased to ¥153,967,470.79 from ¥172,242,746.11, a decline of approximately 10.6%[51]. - The deferred income decreased to ¥15,620,711.78 from ¥19,124,122.83, a reduction of about 18.5%[57]. - The company reported a decrease in other payables to ¥44,795,227.30 from ¥50,488,194.34, a decline of about 11.5%[57]. Research and Development - Research and development expenses grew by 63.12% compared to the same period last year, reflecting the company's intensified R&D efforts, including increased intermediate experiments, material consumption, and clinical research[24]. - Research and development expenses rose to ¥45,726,838.61, up from ¥28,032,869.66, reflecting a significant increase of approximately 63.2%[65]. Other Financial Information - The company received government subsidies totaling ¥4,914,133.26 during the reporting period[9]. - The company reported a fair value change gain of ¥6,707,838.89 from financial assets and derivatives[9]. - The company did not classify any non-recurring gains and losses as recurring during the reporting period[12]. - There were no significant contracts or derivative investments reported during the period[30][32]. - The company's financial expenses showed a notable decrease, with a net financial income of -¥2,908,820.62 compared to ¥10,540,168.18 in the previous period[65]. - The tax expenses for the current period were ¥15,200,032.38, compared to ¥6,268,059.57 in the previous period, indicating an increase of approximately 142.5%[65]. - The company has no overdue or unfulfilled commitments from major shareholders or related parties during the reporting period[25]. - The company has not yet audited the first quarter report, which may impact the reliability of the financial data presented[90].